KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

NovoCure (NVCR) Shares Outstanding (Weighted Average) (2016 - 2026)

NovoCure's Shares Outstanding (Weighted Average) history spans 13 years, with the latest figure at $114.1 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 3.51% to $114.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $114.1 million, a 3.51% increase, with the full-year FY2025 number at $111.5 million, up 3.37% from a year prior.
  • Shares Outstanding (Weighted Average) hit $114.1 million in Q1 2026 for NovoCure, up from $111.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for NVCR hit a ceiling of $114.1 million in Q1 2026 and a floor of $104.2 million in Q1 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $107.7 million across 5 years, with a median of $107.3 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): grew 0.79% in 2022 and later rose 3.6% in 2025.
  • Tracing NVCR's Shares Outstanding (Weighted Average) over 5 years: stood at $104.7 million in 2022, then increased by 1.65% to $106.4 million in 2023, then increased by 1.36% to $107.8 million in 2024, then increased by 3.37% to $111.5 million in 2025, then rose by 2.4% to $114.1 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for NVCR at $114.1 million in Q1 2026, $111.5 million in Q4 2025, and $111.3 million in Q3 2025.